Last updated: May 29, 2026

Application No. 18/153,965

VEGF and TIE2-Binding Fusion Protein and Uses Thereof

Non-Final OA

Filed

Jan 12, 2023

Priority

Jan 13, 2022 — provisional 63/299,177 +2 more

Examiner

COOK, LISA V

Art Unit

1642

Tech Center

1600 — Biotechnology & Organic Chemistry

Assignee

Ingenia Therapeutics Inc.

OA Round

3 (Non-Final)

Interview Optional

— +9.8% interview lift. Interview already conducted in this application's prosecution history. This examiner has a 67% grant rate with +9.8% interview lift. Since an interview has already been tried, recommend written response with narrowed claims based on precedent claim evolution patterns.

Based on 644 resolved cases, 2023–2026

Examiner Intelligence

COOK, LISA V View full profile →

Grants 67% — above average

Career Allowance Rate

433 granted / 644 resolved

+7.2% vs TC avg

Moderate +10% lift

Without

With

+9.8%

Interview Lift

resolved cases with interview

Typical timeline

3y 2m

Avg Prosecution

12 currently pending

Career history

663

Total Applications

across all art units

Statute-Specific Performance

§101

6.6%

-33.4% vs TC avg

§103

44.3%

+4.3% vs TC avg

§102

10.6%

-29.4% vs TC avg

§112

12.1%

-27.9% vs TC avg

Black line = Tech Center average estimate • Based on career data from 644 resolved cases

Prosecution Timeline

Show 5 earlier events

Sep 05, 2025

Response after Non-Final Action

Sep 10, 2025

Final Rejection mailed

Oct 31, 2025

Interview Requested

Nov 11, 2025

Examiner Interview Summary

Jan 05, 2026

Request for Continued Examination

Jan 07, 2026

Response after Non-Final Action

May 12, 2026

Interview Requested

May 21, 2026

Examiner Interview Summary

Precedent Cases

Applications granted by this same examiner with similar technology

17/787,868

Patent 12638450

OVARIAN CANCER BIOMARKER DETECTION THROUGH OVARIAN BLOOD SAMPLING

3y 11m to grant Granted May 26, 2026

17/287,946

Patent 12630626

ANTI-CLDN18.2 ANTIBODY AND USES THEREOF

5y 0m to grant Granted May 19, 2026

17/731,833

Patent 12631643

Tissue-Derived Extracellular Vesicles and Their Use as Diagnostics

4y 0m to grant Granted May 19, 2026

18/537,241

Patent 12631646

Predicting Prognosis and Treatment Response of Breast Cancer Patients Using Expression and Cellular Localization of N-Myristoyltransferase

2y 5m to grant Granted May 19, 2026

17/290,185

Patent 12624086

MATERIALS AND METHODS FOR TREATING CANCER

5y 0m to grant Granted May 12, 2026

Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.

Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4

Expected OA Rounds

67%

Grant Probability

77%

With Interview (+9.8%)

3y 2m (~0m remaining)

Median Time to Grant

High

PTA Risk

Based on 644 resolved cases by this examiner. Grant probability derived from career allowance rate.